Description:
This is a prospective phase II clinical study to be conducted at the Medical College of
Wisconsin. After meeting the study criteria and enrollment, patients will be treated with
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic
intervals to determine the primary and secondary objectives.
Title
- Brief Title: Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
- Official Title: Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
Clinical Trial IDs
- ORG STUDY ID:
PRO29327
- NCT ID:
NCT03150004
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen | Mavenclad, Leustatin, AraC, Cytosar, Novantrone, filgastim, Neupogen, Granix, Zarxio | CLAG-M regimen |
Purpose
This is a prospective phase II clinical study to be conducted at the Medical College of
Wisconsin. After meeting the study criteria and enrollment, patients will be treated with
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) chemotherapy and followed at periodic
intervals to determine the primary and secondary objectives.
Detailed Description
STUDY RATIONALE:
The optimal treatment regimen for relapsed/refractory acute myeloid leukemia (AML) is
unknown. Although several chemotherapy options are available, there is no universally
accepted regimen to date. One such regimen is CLAG-M (Cladribine, Cytarabine, Mitoxantrone,
G-CSF) that has been frequently used at our center. However, it is difficult to predict which
patients are likely to respond to CLAG-M or experience treatment-related toxicities. In
patients with newly diagnosed AML, studies have demonstrated that achievement of minimal
residual disease negative CR is associated with a better overall survival. However, this has
not been clearly studied in patients with relapsed-refractory AML. Through this study, we aim
to demonstrate the influence of achieving MRD negative CR on survival of patients with
relapsed/refractory AML treated with CLAG-M. In addition to the conventionally used
predictive factors, we aim to incorporate pharmacogenomics to assess the efficacy and
toxicity of therapy.
PRIMARY OBJECTIVE:
To determine the complete remission (CR) rate and achievement of minimal residual disease
(MRD) negativity after treatment with salvage CLAG-M chemotherapy regimen in patients with
relapse/refractory and secondary AML.
SECONDARY OBJECTIVES:
1. To determine the progression free survival (PFS) and overall survival (OS) of patients
treated with CLAG-M chemotherapy regimen.
2. To study the pharmacogenomics of patients receiving CLAG-M chemotherapy and determine
its influence on survival, CR rate and MRD negativity.
3. Determination of disease- or patient-related factors that predict MRD negativity and
survival with CLAG-M.
Trial Arms
Name | Type | Description | Interventions |
---|
CLAG-M regimen | Experimental | Patients' treatment cycle is 30 days. | - Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
|
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years at the time of informed consent.
2. Morphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to
Myelodysplastic Syndrome (MDS) or therapy related AML (t-AML), as defined by World
Health Organization (WHO) criteria.
3. Patients must meet one of the following criteria:
- In first or subsequent relapse or refractory status, with or without prior
hematopoietic stem cell transplant (HSCT) OR
- Patients with MDS transformed to AML will be eligible even if they had not
received prior therapy for AML.
4. Eastern Cooperative Oncology Group (ECOG) performance score 0-2.
5. Patients must meet the following clinical laboratory criteria: Direct bilirubin ≤ 1.5
X the upper limit of the normal range (ULN), alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) ≤ 3 X ULN unless related to AML or Gilbert syndrome
or hemolysis. Calculated creatinine clearance ≥30 mL/min
6. Left ventricular ejection fraction (LVEF) ≥ 45%
Exclusion Criteria:
1. Acute Promyelocytic Leukemia.
2. Pregnant or breast feeding women.
3. Participation in clinical trials with other investigational agents not included in
this trial, within 14 days of the start of this trial and throughout the duration of
this trial.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Minimal residual disease (MRD) complete remission (CR) rate |
Time Frame: | Day 35 |
Safety Issue: | |
Description: | The number of participants who achieve MRD CR. Repeat bone marrow study will be obtained after the completion of CLAG-M therapy at day 30 or when absolute neutrophil count (ANC) recovers to >1000 cells/^3. |
Secondary Outcome Measures
Measure: | Overall survival |
Time Frame: | Year 4 |
Safety Issue: | |
Description: | The number of participants still alive following CLAG-M chemotherapy. |
Measure: | Prediction of minimal residual disease (MRD) negativity |
Time Frame: | Day 5 |
Safety Issue: | |
Description: | The number of participants predicted to have no minimal residual disease, using pharmacogenomics. |
Measure: | Prediction of the development of treatment-related toxicities |
Time Frame: | Day 5 |
Safety Issue: | |
Description: | The number of participants predicted to have treatment-related toxicities, using pharmacogenomics. |
Measure: | Progression-free survival |
Time Frame: | Year 4 |
Safety Issue: | |
Description: | The number of participants who don't experience progressive disease. |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Medical College of Wisconsin |
Trial Keywords
- Acute myeloid leukemia
- AML
- salvage chemotherapy
- CLAG-M
- relapse acute myeloid leukemia
- secondary acute myeloid leukemia
- phase II
- pharmacogenomics
Last Updated
April 1, 2021